Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

The Clinical Effectiveness of Fidaxomicin Compared to Vancomycin in the Treatment of Clostridioides difficile Infection, A Single-Center Real-World Experience

The Journal of Infectious Diseases(2024)10.1093/infdis/jiae274Source: DataRank Database

The Clinical Effectiveness of Fidaxomicin Compared to Vancomycin in the Treatment of Clostridioides difficile Infection, A Single-Center Real-World Experience is a research paper published in The Journal of Infectious Diseases (2024). On theSindex it has a DataRank of 0. It has been cited 5 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access5 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (9 grants)Impact (FWCI 1.51)OA: greenTopics (52)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (7)

Jennifer Chow ORCID,Angie Mae Rodday ORCID,L. A. McDermott,Seth T. Walk ORCID,David M. Kent ORCID

Live enrichment

PubMed:38779889 PMC:PMC11646585 OpenAlex:https://openalex.org/W4398761426

National Institutes of Health

Grant: UL1TR002544

National Center for Advancing Translational Sciences

Tupper Family Foundation

Merck & Co

Tufts Medical Center;

Merck & Co

Tupper Family Foundation

Tufts Medical Center;

Merck & Co

FWCI

1.51

Citation Percentile

0.8%

Citation Trend

2025

2026

green

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11646585/pdf/jiae274.pdf

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/11646585

journalhttps://doi.org/10.1093/infdis/jiae274

repositoryhttps://pubmed.ncbi.nlm.nih.gov/38779889

Fields of Study

Clostridium difficile and Clostridium perfringens researchAntimicrobial Resistance in StaphylococcusNosocomial Infections in ICUHumansFidaxomicinVancomycinFemaleMaleClostridium InfectionsRetrospective StudiesAnti-Bacterial AgentsAgedMiddle AgedClostridioides difficileTreatment OutcomeRecurrenceAged, 80 and overProportional Hazards ModelsRibotyping

MeSH Terms

FidaxomicinAgedAged, 80 and overAnti-Bacterial AgentsClostridium InfectionsFemaleHumansMaleMiddle AgedRecurrenceRetrospective StudiesVancomycinProportional Hazards ModelsClostridioides difficileTreatment OutcomeRibotyping

Keywords

FidaxomicinClostridioidesMedicineVancomycinSingle CenterC difficileInternal medicineIntensive care medicineClostridium difficileMicrobiologyAntibioticsBacteriaBiologyCDIRibotype 027Oral VancomycinClostridioides Difficile

Sustainable Development Goals

SDG 0: Good health and well-being